At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Trial of Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
In Brief
A Phase 4 clinical trial evaluating GLP-1 medication for Diabetes Mellitus, Type 2 and 2 related conditions. Completed, enrolled 69 participants across 2 sites.
Detailed Summary
To assess whether holding incretin-based therapy before endoscopy reduces the likelihood of clinically relevant Residual Gastric Volume (RGV). Primary Outcomes: * Residual gastric volume that precludes adequate endoscopic examination * Residual gastric volume that necessitates premature termination of the endoscopy procedure * Need for endotracheal intubation due to stomach contents. * Occurrence of aspiration events requiring extended observation/monitoring, unplanned therapeutics, and/or hospital admission Secondary Outcomes: * Presence of any solid food * Presence of moderate liquid content * Increased RGV(Residual Gastric Volume) defined as any amount of solid content or \> 0.8 mL/Kg of fluid content (measured from the aspiration/suction canister). * Differences in primary and secondary outcomes between different medications
Study Details
Timeline
Interventions
Continue taking GLP-1 as normally scheduled prior to endoscopy.